Uneven Implementation of Nirsevimab Prophylaxis Resulted in Non-Uniform Reductions in RSV-Related Hospitalizations in Italy

Background/Objectives: Respiratory syncytial virus (RSV) bronchiolitis remains a leading cause of hospitalization in infants. In the 2024–2025 season, passive newborn immunization with nirsevimab, a long-acting anti-RSV monoclonal antibody, was introduced for the first time in Italy. However, the im...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Melodie O. Aricò, Francesco Accomando, Daniela Trotta, Giulia Marozzi, Anthea Mariani, Claudia Rossini, Claudio Cafagno, Letizia Lorusso, Martina Fornaro, Enrico Valletta, Désirée Caselli, Maurizio Aricò
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	MDPI AG 2025-09-01
Saila:	Infectious Disease Reports
Gaiak:	bronchiolitis respiratory syncytial virus nirsevimab health disparities
Sarrera elektronikoa:	https://www.mdpi.com/2036-7449/17/5/115
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!